HRT and heart disease: Dr Jekyll or Mrs Hyde?

Maturitas

Volumn 38, Issue 3, 2001, Pages 213-217

  Van Der Schouw, Yvonne T ^a   Grobbee, Diederick E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; PLACEBO; SEX HORMONE;

ALCOHOL CONSUMPTION; ATHEROSCLEROSIS; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; EDITORIAL; HEART PROTECTION; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; MENOPAUSE; MORBIDITY; NONHUMAN; OBESITY; OVARIECTOMY; SPORT; THROMBOSIS;

CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HEART DISEASES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS;

EID: 0343844177     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(01)00176-1     Document Type: Editorial

References (41)

1. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B., Speizer F.E., Hennekens C.H. Menopause and the risk of coronary heart disease in women. New Engl. J. Med. 316:1987;1105-1110.
2. Gordon T., Kannel W.B., Hjortland M.C., McNamara P.M. Menopause and coronary heart disease: the Framingham study. Ann. Intern. Med. 89:1978;157-161.
3. Grodstein F., Manson J.E., Colditz G.A., Willett W.C., Speizer F.E., Stampfer M.J. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann. Intern. Med. 133:2000;933-941.
4. Stampfer M.J., Colditz G.A. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev. Med. 20:1991;47-63.
5. Avila M.H., Walker A.M., Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology. 1:1990;128-133.
6. Henderson B.E., Paganini-Hill A., Ross R.K. Decreased mortality in users of estrogen replacement therapy. Arch. Intern. Med. 151:1991;75-78.
7. Falkeborn M., Persson I., Adami H.O., Bergstrom R., Eaker E., Lithell H., et al. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br. J. Obstet. Gynaecol. 99:1992;821-828.
8. Rosenberg L., Palmer J.R., Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am. J. Epidemiol. 137:1993;54-63.
9. Mann R.D., Lis Y., Chukwujindu J., Chanter D.O. A study of the association between hormone replacement therapy, smoking and the occurrence of myocardial infarction in women. J. Clin. Epidemiol. 47:1994;307-312.
10. Brett K.M., Madans J.H. Long-term survival after coronary heart disease. Comparisons between men and women in a national sample. Ann. Epidemiol. 5:1995;25-32. see comments.
11. Newton K.M., LaCroix A.Z., McKnight B., Knopp R.H., Siscovick D.S., Heckbert S.R., et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am. J. Epidemiol. 145:1997;269-277.
12. Heckbert S.R., Weiss N.S., Koepsell T.D., Lemaitre R.N., Smith N.L., Siscovick D.S., et al. Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. Arch. Intern. Med. 157:1997;1330-1336.
13. Sidney S., Petitti D.B., Quesenberry C.P. Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann. Intern. Med. 127:1997;501-508.
14. Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Rosner B., Speizer F.E., et al. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. New Engl. J. Med. 325:1991;756-762.
15. Grodstein F., Stampfer M.J., Manson J.E., Colditz G.A., Willett W.C., Rosner B., et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. New Engl. J. Med. 335:1996;453-461.
16. Ettinger B., Friedman G.D., Bush T., Quesenberry C.P. Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet. Gynecol. 87:1996;6-12.
17. Grodstein F., Stampfer M.J., Colditz G.A., Willett W.C., Manson J.E., Joffe M., et al. Postmenopausal hormone therapy and mortality. New Engl. J. Med. 336:1997;1769-1775. see comments.
18. Cauley J.A., Cummings S.R., Black D.M., Mascioli S.R., Seeley D.G. Prevalence and determinants of estrogen replacement therapy in elderly women. Am. J. Obstet. Gynecol. 163:1990;1438-1444.
19. Hemminki E., Malin M., Topo P. Selection to postmenopausal therapy by women's characteristics. J. Clin. Epidemiol. 46:1993;211-219.
20. Posthuma W.F.M., Westendorp R.G.J., Vandenbroucke J.P. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? Br. Med. J. 308:1994;1268-1269.
21. Nachtigall L.E., Nachtigall R.H., Nachtigall R.D., Beckman E.M. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet. Gynecol. 54:1979;74-79.
22. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J. Am. Med. Assoc. 280:1998;605-613. see comments.
23. Adams M.R., Register T.C., Golden D.L., Wagner J.D., Williams J.K. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;217-221.
24. Register T.C., Adams M.R., Golden D.L., Clarkson T.B. Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler. Thromb. Vasc. Biol. 18:1998;1164-1171.
25. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. J. Am. Med. Assoc. 273:1995;199-208.
26. Herrington D.M., Reboussin D.M., Brosnihan K.B., Sharp P.C., Shumaker S.A., Snyder T.E., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. New Engl. J. Med. 343:2000;522-529. see comments.
27. Nabel E.G. Coronary heart disease in women - an ounce of prevention. New Engl. J. Med. 343:2000;572-574. see comment/editorial.
28. Wuest J.H., Dry T.J., Edwards J.E. The degree of coronary atherosclerosis in bilaterally oophorectomized women. Circulation. 8:1953;801-808.
29. Sznajderman M., Oliver M.F. Spontaneous premature menopause, ischaemic heart-disease, and serum-lipids. Lancet. 1:1963;962-965.
30. Robinson R.W., Higano N., Cohen W.D. Increased incidence of coronary heart disease in women castrated prior to the menopause. Arch. Intern. Med. 104:1959;908-913.
31. Jacobsen B.K., Nilssen S., Heuch I., Kvale G. Does age at natural menopause affect mortality from ischemic heart disease? J. Clin. Epidemiol. 50:1997;475-479.
32. Schouw van der Y.T., Graaf van der Y., Steyerberg E.W., Eijkemans M.J.C., Banga J.D. Age at menopause as a risk factor for cardiovascular mortality. Lancet. 347:1996;714-718.
33. Hu F.B., Grodstein F., Hennekens C.H., Colditz G.A., Johnson M., Manson J.E., et al. Age at natural menopause and risk of cardiovascular disease. Arch. Intern. Med. 159:1999;1061-1066.
34. Nabulsi A.A., Folsom A.R., White A., Patsch W., Heiss G., Wu K.K., et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. New Engl. J. Med. 328:1993;1069-1075. see comments.
35. Herrington D.M., Braden G.A., Williams J.K., Morgan T.M. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am. J. Cardiol. 73:1994;951-952.
36. Williams J.K., Adams M.R., Herrington D.M., Clarkson T.B. Short-term administration of estrogen and vascular responses of atherosclerotic coronary arteries. J. Am. Coll. Cardiol. 20:1992;452-457.
37. Lim S.C., Caballero A.E., Arora S., Smakowski P., Bashoff E.M., Brown F.M., et al. The effect of hormonal replacement therapy on the vascular reactivity and endothelial function of healthy individuals and individuals with type 2 diabetes. J. Clin. Endocrinol. Metab. 84:1999;4159-4164.
38. Perregaux D., Chaudhuri A., Mohanty P., Bukhari L., Wilson M.F., Sung B.H., et al. Effect of gender differences and estrogen replacement therapy on vascular reactivity. Metabolism. 48:1999;227-232.
39. Pinto S., Virdis A., Ghiadoni L., Bernini G., Lombardo M., Petraglia F., et al. Endogenous estrogen and acetylcholine-induced vasodilation in normotensive women. Hypertension. 29:1997;268-273.
40. McCrohon J.A., Adams M.R., McCredie R.J., Robinson J., Pike A., Abbey M., et al. Hormone replacement therapy is associated with improved arterial physiology in healthy post-menopausal women. Clin. Endocrinol. (Oxford). 45:1996;435-441.
41. Grodstein F., Manson J.E., Stampfer M. Postmenopausal hormones and recurrence of coronary events. Circulation. 100:2001;S18-18. Abstract.